SOURCE MEDICINE

Company limited by guarantee

Company Registration Number:
10085231 (England and Wales)

Unaudited statutory accounts for the year ended 31 March 2024

Period of accounts

Start date: 1 April 2023

End date: 31 March 2024

SOURCE MEDICINE

Contents of the Financial Statements

for the Period Ended 31 March 2024

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes

SOURCE MEDICINE

Directors' report period ended 31 March 2024

The directors present their report with the financial statements of the company for the period ended 31 March 2024

Directors

The director shown below has held office during the whole of the period from
1 April 2023 to 31 March 2024

Leilani Silvia Ashmole van Koten


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
25 July 2024

And signed on behalf of the board by:
Name: Leilani Silvia Ashmole van Koten
Status: Director

SOURCE MEDICINE

Profit And Loss Account

for the Period Ended 31 March 2024

2024 2023


£

£
Turnover: 6,328 16,827
Cost of sales: ( 1,164 ) ( 1,480 )
Gross profit(or loss): 5,164 15,347
Administrative expenses: ( 10,181 ) ( 11,917 )
Operating profit(or loss): (5,017) 3,430
Interest payable and similar charges: ( 62 )
Profit(or loss) before tax: (5,079) 3,430
Tax: ( 652 )
Profit(or loss) for the financial year: (5,079) 2,778

SOURCE MEDICINE

Balance sheet

As at 31 March 2024

Notes 2024 2023


£

£
Current assets
Cash at bank and in hand: 5,526 12,753
Total current assets: 5,526 12,753
Creditors: amounts falling due within one year: 3 ( 702 ) ( 1,262 )
Net current assets (liabilities): 4,824 11,491
Total assets less current liabilities: 4,824 11,491
Creditors: amounts falling due after more than one year: 4 ( 3,290 ) ( 4,878 )
Total net assets (liabilities): 1,534 6,613
Members' funds
Profit and loss account: 1,534 6,613
Total members' funds: 1,534 6,613

The notes form part of these financial statements

SOURCE MEDICINE

Balance sheet statements

For the year ending 31 March 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 25 July 2024
and signed on behalf of the board by:

Name: Leilani Silvia Ashmole van Koten
Status: Director

The notes form part of these financial statements

SOURCE MEDICINE

Notes to the Financial Statements

for the Period Ended 31 March 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

SOURCE MEDICINE

Notes to the Financial Statements

for the Period Ended 31 March 2024

  • 2. Employees

    2024 2023
    Average number of employees during the period 0 0

SOURCE MEDICINE

Notes to the Financial Statements

for the Period Ended 31 March 2024

3. Creditors: amounts falling due within one year note

2024 2023
£ £
Taxation and social security 652
Accruals and deferred income 702 610
Total 702 1,262

SOURCE MEDICINE

Notes to the Financial Statements

for the Period Ended 31 March 2024

4. Creditors: amounts falling due after more than one year note

2024 2023
£ £
Other creditors 3,290 4,878
Total 3,290 4,878